Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Addressing genetic tumor heterogeneity through computationally predictive combination therapy.

Zhao B, Pritchard JR, Lauffenburger DA, Hemann MT.

Cancer Discov. 2014 Feb;4(2):166-74. doi: 10.1158/2159-8290.CD-13-0465. Epub 2013 Dec 6.

PMID:
24318931
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Intratumor heterogeneity alters most effective drugs in designed combinations.

Zhao B, Hemann MT, Lauffenburger DA.

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10773-8. doi: 10.1073/pnas.1323934111. Epub 2014 Jul 7.

PMID:
25002493
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.

Terranova N, Germani M, Del Bene F, Magni P.

Cancer Chemother Pharmacol. 2013 Aug;72(2):471-82. doi: 10.1007/s00280-013-2208-8. Epub 2013 Jun 29.

PMID:
23812004
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Modeling of tumor growth and anticancer effects of combination therapy.

Koch G, Walz A, Lahu G, Schropp J.

J Pharmacokinet Pharmacodyn. 2009 Apr;36(2):179-97. doi: 10.1007/s10928-009-9117-9. Epub 2009 Apr 22.

PMID:
19387803
[PubMed - indexed for MEDLINE]
5.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
[PubMed - indexed for MEDLINE]
6.

Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model.

Sabnis GJ, Macedo L, Goloubeva O, Schayowitz A, Zhu Y, Brodie A.

J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7. Epub 2007 Sep 7.

PMID:
17942301
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.

Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS.

Mol Cancer Ther. 2006 Jul;5(7):1854-63.

PMID:
16891472
[PubMed - indexed for MEDLINE]
Free Article
8.

Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.

Joshi AD, Loilome W, Siu IM, Tyler B, Gallia GL, Riggins GJ.

PLoS One. 2012;7(10):e44372. doi: 10.1371/journal.pone.0044372. Epub 2012 Oct 2.

PMID:
23056179
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.

Reddy JA, Dorton R, Bloomfield A, Nelson M, Vetzel M, Guan J, Leamon CP.

Clin Cancer Res. 2014 Apr 15;20(8):2104-14. doi: 10.1158/1078-0432.CCR-13-2423. Epub 2014 Jan 15.

PMID:
24429878
[PubMed - indexed for MEDLINE]
10.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

PMID:
21163770
[PubMed - indexed for MEDLINE]
Free Article
11.

Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.

Rocchetti M, Germani M, Del Bene F, Poggesi I, Magni P, Pesenti E, De Nicolao G.

Cancer Chemother Pharmacol. 2013 May;71(5):1147-57. doi: 10.1007/s00280-013-2107-z. Epub 2013 Feb 21.

PMID:
23430120
[PubMed - indexed for MEDLINE]
12.

Defining principles of combination drug mechanisms of action.

Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT.

Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):E170-9. doi: 10.1073/pnas.1210419110. Epub 2012 Dec 18.

PMID:
23251029
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
[PubMed - indexed for MEDLINE]
14.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
[PubMed - indexed for MEDLINE]
15.

Synopsis of a roundtable on validating novel therapeutics for multiple myeloma.

Dalton W, Anderson KC.

Clin Cancer Res. 2006 Nov 15;12(22):6603-10. Review.

PMID:
17121878
[PubMed - indexed for MEDLINE]
Free Article
16.

In vivo/ex vivo and in situ assays used in cancer research: a brief review.

Teicher BA.

Toxicol Pathol. 2009 Jan;37(1):114-22. doi: 10.1177/0192623308329473. Epub 2008 Dec 19. Review.

PMID:
19098118
[PubMed - indexed for MEDLINE]
Free Article
17.

Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.

Quesnelle KM, Grandis JR.

Clin Cancer Res. 2011 Sep 15;17(18):5935-44. doi: 10.1158/1078-0432.CCR-11-0370. Epub 2011 Jul 26.

PMID:
21791633
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.

Poste G.

Cancer Treat Rep. 1986 Jan;70(1):183-99. Review.

PMID:
3510734
[PubMed - indexed for MEDLINE]
19.

Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.

Harada K, Ferdous T, Itashiki Y, Takii M, Mano T, Mori Y, Ueyama Y.

Anticancer Res. 2009 Apr;29(4):1263-70.

PMID:
19414373
[PubMed - indexed for MEDLINE]
Free Article
20.

Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.

Abolhassani M, Guais A, Sanders E, Campion F, Fichtner I, Bonte J, Baronzio G, Fiorentini G, Israël M, Schwartz L.

Invest New Drugs. 2012 Aug;30(4):1331-42. doi: 10.1007/s10637-011-9692-7. Epub 2011 Jun 9.

PMID:
21655919
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk